FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140688108> ?p ?o ?g. }

• W2140688108 endingPage "22" @default.
• W2140688108 startingPage "14" @default.
• W2140688108 abstract "To present our experience using a twice-daily radiotherapy (RT) technique, including hyperfractionated and accelerated-hyperfractionated RT, on nasopharyngeal carcinoma (NPC) patients. The dose to the primary tumor was increased in the hope that local control could be increased without the cost of increased late complications. We analyzed acute and late complications and local control and compared the results with the results of NPC patients treated during the same period using conventional once-daily RT.Between October 1991 and July 1998, 222 histologically confirmed, Stage M0, previously unirradiated NPC patients completed RT at our hospital. Most patients had American Joint Committee on Cancer (AJCC) 1992 Stage III and IV disease. Among them, 88 received altered fractionated, twice-daily RT; 76 patients received hyperfractionated RT and 12 accelerated-hyperfractionated RT. The remaining 134 patients received a conventional once-daily regimen. Hyperfractionated RT was delivered using 120 cGy b.i.d. separated by 6-h intervals throughout the course. For the accelerated-hyperfractionated patients, 160 cGy b.i.d. was given, also at 6-h intervals. The median dose in the twice-daily group was 7810 cGy (range 6840-8200). In the once-daily regimen, RT was delivered using 180-200 cGy q.d. The median tumor dose to the primary tumor was 7000 cGy (range 6560-8100) given during about 8 weeks. The median follow-up time was 70.5 and 72 months for the twice-daily and once-daily groups, respectively.The incidence of acute toxicities was higher in the twice-daily group with more severe mucositis and moist desquamation than in the once-daily group. Both groups had a similar incidence of late complications, except for 3 cases of temporal lobe necrosis in the twice-daily group, all in patients treated with 160 cGy. No difference was noted in recurrence-free local control between the two groups when the individual T stage was compared using AJCC 1992 or 1997 criteria (p = 0.51 and 0.59, respectively). The 5-year local control rate for T1-3 (AJCC 1997) was 93.2% for the twice-daily group and 86.4% for the once-daily group (p = 0.45). In Stage T4 (AJCC 1997) patients, the local control rate dropped drastically to 43.5% and 36.9% for the twice-daily and once-daily groups, respectively. The overall neck control rate at 5 years was 87.3% and 80.3% for the twice-daily and once-daily patients, respectively (p = 0.16). The overall locoregional control rate was 82.7% for the twice-daily group and 66.6% for the once-daily group. The difference was again not statistically significant, but showed a tendency in favor of the twice-daily regimen (p = 0.055). Locoregional failure occurred mainly in Stage T4 patients with central nervous invasion for whom local control was particularly poor, with a failure rate of about 60%.The present data suggest that NPC patients can be safely treated using a 120-cGy twice-daily program with a 6-h interval up to 8000 cGy. The accelerated-hyperfractionated technique is not recommended. A large discrepancy in local control between patients with T1-3 and T4 disease was noted. For T1-3 disease, an excellent local control rate >90% was achieved using the twice-daily regimen. In contrast, failure in the T4 patients was as high as 55% in the twice-daily group and reached 65% in the once-daily group. More rigorous treatment is needed using either additional dose escalation or other strategies for T4 NPC patients. With a dose escalation of 1000 cGy using 120-cGy twice-daily RT, a trend toward better locoregional control and disease-specific survival was noted in the twice-daily group. Whether this difference was truly the result of an increased dose needs additional confirmation in studies with larger patient numbers." @default.
• W2140688108 created "2016-06-24" @default.
• W2140688108 creator A5008429493 @default.
• W2140688108 creator A5012209697 @default.
• W2140688108 creator A5015178631 @default.
• W2140688108 creator A5025899152 @default.
• W2140688108 creator A5038753623 @default.
• W2140688108 creator A5050234054 @default.
• W2140688108 creator A5058462790 @default.
• W2140688108 creator A5068850034 @default.
• W2140688108 creator A5072320834 @default.
• W2140688108 creator A5078969099 @default.
• W2140688108 creator A5086546681 @default.
• W2140688108 creator A5089179749 @default.
• W2140688108 date "2002-09-01" @default.
• W2140688108 modified "2023-10-18" @default.
• W2140688108 title "Dose escalation using twice-daily radiotherapy for nasopharyngeal carcinoma: does heavier dosing result in a happier ending?" @default.
• W2140688108 cites W1970804580 @default.
• W2140688108 cites W1971747664 @default.
• W2140688108 cites W1984496741 @default.
• W2140688108 cites W1985875228 @default.
• W2140688108 cites W1991735979 @default.
• W2140688108 cites W1994752875 @default.
• W2140688108 cites W2016871222 @default.
• W2140688108 cites W2020693781 @default.
• W2140688108 cites W2022795082 @default.
• W2140688108 cites W2026631273 @default.
• W2140688108 cites W2029517266 @default.
• W2140688108 cites W2058069994 @default.
• W2140688108 cites W2085409346 @default.
• W2140688108 cites W2090965770 @default.
• W2140688108 cites W2095430487 @default.
• W2140688108 cites W2097426900 @default.
• W2140688108 cites W2105934027 @default.
• W2140688108 cites W2124650760 @default.
• W2140688108 cites W2133555954 @default.
• W2140688108 cites W2135426130 @default.
• W2140688108 cites W2154519881 @default.
• W2140688108 cites W2158044679 @default.
• W2140688108 cites W4242686916 @default.
• W2140688108 doi "https://doi.org/10.1016/s0360-3016(02)02914-0" @default.
• W2140688108 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12182970" @default.
• W2140688108 hasPublicationYear "2002" @default.
• W2140688108 type Work @default.
• W2140688108 sameAs 2140688108 @default.
• W2140688108 citedByCount "31" @default.
• W2140688108 countsByYear W21406881082012 @default.
• W2140688108 countsByYear W21406881082013 @default.
• W2140688108 countsByYear W21406881082014 @default.
• W2140688108 countsByYear W21406881082015 @default.
• W2140688108 countsByYear W21406881082019 @default.
• W2140688108 countsByYear W21406881082020 @default.
• W2140688108 countsByYear W21406881082021 @default.
• W2140688108 countsByYear W21406881082022 @default.
• W2140688108 countsByYear W21406881082023 @default.
• W2140688108 crossrefType "journal-article" @default.
• W2140688108 hasAuthorship W2140688108A5008429493 @default.
• W2140688108 hasAuthorship W2140688108A5012209697 @default.
• W2140688108 hasAuthorship W2140688108A5015178631 @default.
• W2140688108 hasAuthorship W2140688108A5025899152 @default.
• W2140688108 hasAuthorship W2140688108A5038753623 @default.
• W2140688108 hasAuthorship W2140688108A5050234054 @default.
• W2140688108 hasAuthorship W2140688108A5058462790 @default.
• W2140688108 hasAuthorship W2140688108A5068850034 @default.
• W2140688108 hasAuthorship W2140688108A5072320834 @default.
• W2140688108 hasAuthorship W2140688108A5078969099 @default.
• W2140688108 hasAuthorship W2140688108A5086546681 @default.
• W2140688108 hasAuthorship W2140688108A5089179749 @default.
• W2140688108 hasConcept C120665830 @default.
• W2140688108 hasConcept C121332964 @default.
• W2140688108 hasConcept C126322002 @default.
• W2140688108 hasConcept C141071460 @default.
• W2140688108 hasConcept C146357865 @default.
• W2140688108 hasConcept C151730666 @default.
• W2140688108 hasConcept C155806632 @default.
• W2140688108 hasConcept C2777288759 @default.
• W2140688108 hasConcept C2778997737 @default.
• W2140688108 hasConcept C2781413609 @default.
• W2140688108 hasConcept C2908786992 @default.
• W2140688108 hasConcept C2989005 @default.
• W2140688108 hasConcept C509974204 @default.
• W2140688108 hasConcept C61511704 @default.
• W2140688108 hasConcept C71924100 @default.
• W2140688108 hasConcept C86803240 @default.
• W2140688108 hasConceptScore W2140688108C120665830 @default.
• W2140688108 hasConceptScore W2140688108C121332964 @default.
• W2140688108 hasConceptScore W2140688108C126322002 @default.
• W2140688108 hasConceptScore W2140688108C141071460 @default.
• W2140688108 hasConceptScore W2140688108C146357865 @default.
• W2140688108 hasConceptScore W2140688108C151730666 @default.
• W2140688108 hasConceptScore W2140688108C155806632 @default.
• W2140688108 hasConceptScore W2140688108C2777288759 @default.
• W2140688108 hasConceptScore W2140688108C2778997737 @default.
• W2140688108 hasConceptScore W2140688108C2781413609 @default.
• W2140688108 hasConceptScore W2140688108C2908786992 @default.
• W2140688108 hasConceptScore W2140688108C2989005 @default.
• W2140688108 hasConceptScore W2140688108C509974204 @default.
• W2140688108 hasConceptScore W2140688108C61511704 @default.

• next